7494-71-5

Usage

Type of compound

Purine derivative (heterocyclic compound with nitrogen and oxygen atoms in its ring structure)

Derivative of

Nucleotide base purine

Pharmaceutical applications

Potential anticancer, antiviral, and protein kinase inhibitory properties

Effects on angiogenesis

Promising effects on the formation of blood vessels, making it potentially important for the treatment of diseases and conditions related to abnormal blood vessel formation.

Upstream product

• 110-91-8 morpholine 
• 5451-40-1 2,6-dichloro-7H-purine 
• 4010-81-5 4-(2-chloro-9H-purin-6-yl)morpholine 
• 5451-40-1 2,6 dichloropurine 

Relevant academic research and scientific papers

Design, Synthesis, and Biological Evaluation of Dimorpholine Substituted Thienopyrimidines as Potential Class I PI3K/mTOR Dual Inhibitors

Dysfunctional signaling of the PI3K/AKT/mTOR pathway in cancer and its crucial role in cell growth and survival have made it a much desired target for cancer therapeutics. A series of dimorpholine substituted thienopyrimidine derivatives had been prepared and evaluated in vitro and in vivo. Among them, compound 14o was identified as a dual Class I PI3K and mTOR kinase inhibitor, which had an approximately 8-fold improvement in mTOR inhibition relative to the class I PI3K inhibitor 1 (pictilisib, GDC-0941). Western blot analysis confirmed the 14o mechanistic modulation of the cellular PI3K/AKT/mTOR pathway through inhibiting phosphorylation of both AKT and S6 in human cancer cell lines. In addition, 14o demonstrated significant efficacy in SKOV-3 and U87MG tumor xenograft models without causing significant weight loss and toxicity.

Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss

This invention relates to pyrimidine compounds of formula (I), formula (I′), and formula (I″): and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R1, R2, R3, R4, R5/

Novel compounds

This invention features a compound of formula (I): R1 is aryl or heteroaryl; each of R2 and R4, independently, is H, halogen, CN, alkyl, ORa, or NRaRb; R3 is H, halogen, CN, alky

Solution-phase synthesis of 2,6,9-trisubstituted purines

A simple three-step method for the solution-phase combinatorial synthesis of 2,6,9-trisubstituted purines from 2,6-dichloropurine is described. The synthesis exploits the use of resin capture to remove excess reagent used in the final step.